Akari Therapeutics AKTX 深 沪
等待开盘 05-19 09:30:00 美东时间
3.50
+0.010
+0.29%
华盛通- 最 高3.6667
- 今 开3.39
- 成交量 9769股
- 最 低 3.39
- 昨 收 3.49
- 总市值 400.61万
- 52周最高 56.80
- 市盈率 静 --
- 换手率 0.85%
- 52周最低 3.015
- 委 比 -82.65%
- 总股本 114.46万
- 历史最高 95200.00
- 量 比 0.19
- 振 幅 7.93%
- 历史最低 3.39
- 每 手 1
- 风险率 16.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Akari Therapeutics Stock Is Surging On Thursday?
Akari Therapeutics PLC (NASDAQ:AKTX) sees stock growth fueled by Q1 2026 earnings optimism and a new European patent for its PH1 ADC payload.
05-15 00:04
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock moved upwards by 79.4% to $12....
05-13 01:06
Akari Therapeutics Granted European Patent For Proprietary ADC Payload Platform Technology
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the grant of a major European patent that
05-12 20:35
Akari Therapeutics' AKTX-101 Shows Superior Preclinical Potency Versus Leading TROP2 ADCs Across Bladder, Lung, And Breast Cancer Models
Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor modelsNovel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor resistancePreclinical
04-20 20:36
Maxim Group Downgrades Akari Therapeutics to Hold
Maxim Group analyst Jason McCarthy downgrades Akari Therapeutics (NASDAQ:AKTX) from Buy to Hold.
04-08 21:22
Akari Therapeutics Collaborates With WuXi XDC Over Development Of Novel PH1 Payload
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads announced a strategic partnership with WuXi XDC, a
04-06 20:46
Akari Therapeutics Announces 1-For-40 ADS Ratio Change, Effective March 31, 2026.
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced that the Company will change the ratio of its
03-18 04:34
Akari Therapeutics Announces ADS Ratio Change
Akari Therapeutics announced it will change the ADS to ordinary shares ratio from 1 ADS representing 2,000 shares to 80,000 shares, effective March 31, 2026. This change aims to maintain compliance with Nasdaq's minimum bid price requirements. ADS holders must exchange 40 old ADSs for 1 new ADS. Deutsche Bank will handle the exchange. Akari's ordinary shares remain unchanged, and ADSs will continue trading on NASDAQ under AKTX. No fractional ADSs...
03-17 20:30
Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala
Akari Therapeutics under Abizer Gaslightwala's leadership has made significant progress, including advancing its lead ADC program AKTX-101, expanding its pipeline with AKTX-102, and strengthening its IP portfolio. The company has also partnered with WuXi XDC to advance AKTX-101 toward clinical trials, with an IND/CTA expected in late 2026/early 2027. These advancements position Akari as a clinical-stage biotech with a promising pipeline and innov...
03-13 13:15
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
Akari Therapeutics has appointed Prafulla Gokhale, Ph.D., a cancer biology and RNA biology expert with over 20 years of experience, to its Scientific Advisory Board. Gokhale's expertise will support the development of AKTX-101, an antibody drug conjugate (ADC) targeting RNA splicing. Akari's PH1 payload differs from conventional ADCs by targeting splicing, potentially disrupting tumor survival and engaging immune responses. Gokhale's insights wil...
02-26 14:10
